CMS announced a final payment notice for the 2021 coverage year; experts say children should be more well-represented in coronavirus disease 2019 (COVID-19) clinical trials; a new report predicts sharp increases in deaths of despair resulting from the pandemic.
CMS issued a final payment notice for the 2021 coverage year in addition to a 1-week extension of the Qualified Health Plan certification and rate review timelines. This extra time is intended to allow issuers and states to accurately collect and assess data from the coronavirus disease 2019 (COVID-19) pandemic. By doing so, CMS claims more accurate premium rates can be established. The payment notice also continues lower user fee rates on issuers in the federal exchange platform that were originally set in the 2020 notice. The notice also requires states to annually notify CMS of any additional state-required benefit mandates and to defray the cost of new state-mandated insurance benefits in addition to essential health benefits.Some doctors are calling for increased inclusion of children in COVID-19 trials, according to an article published in JAMA Pediatrics. Of the 275 COVID-19 interventional trials conducted between February 1 and April 11, 2020, only 30 were open to enrolling patients under the age of 18. Authors argue a lack of pediatric data for a treatment at the time of regulatory approval could expose children to ineffective dosing or unsafe treatments. Although early reports suggest COVID-19 may be milder in children, researchers point out the infection can be serious in certain pediatric populations. Public health agencies, regulators, and trial investigators and sponsors should act to ensure pediatric labeling data on new products’ market entries are available, researchers conclude.Deaths due to drug and alcohol use, and suicide, or deaths of despair, may rise due to the current COVID-19 pandemic, according to a new report released by the Well Being Trust and Robert Graham Center. Three main factors potentially contributing to the predicted rise are high unemployment rates, mandated social isolation, and uncertainty and anxiety caused by the emergence of a new microbe. Researchers feel deaths of despair ought to be considered as an epidemic within the pandemic. After investigating 9 different scenarios, they found additional deaths of despair could range from 27,644 to 154,037 based on varying recovery times and impacts of unemployment.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Wearable Activity Tracker Data Enhance Patient Assessment in Lung Cancer
March 28th 2024This analysis included 119 patients with advanced lung cancer, who were evaluated on 3 facets of physical activity over 14 days of using the amuelink wearable device from Sony: metabolic equivalent tasks, distance walked, and steps taken.
Read More